Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. Ferguson BD, et al. Among authors: vokes ee. PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013. PLoS One. 2013. PMID: 23844053 Free PMC article.
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. Kindler HL, et al. Among authors: vokes ee. Invest New Drugs. 2004 Aug;22(3):323-7. doi: 10.1023/B:DRUG.0000026259.28395.c2. Invest New Drugs. 2004. PMID: 15122080 Clinical Trial.
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Cohen EE, et al. Among authors: vokes ee. Clin Cancer Res. 2005 Nov 15;11(22):8105-8. doi: 10.1158/1078-0432.CCR-05-0926. Clin Cancer Res. 2005. PMID: 16299242
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. Seiwert TY, et al. Among authors: vokes ee. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22. doi: 10.1158/1078-0432.CCR-06-1058. Clin Cancer Res. 2007. PMID: 17255273 Clinical Trial.
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM. Choong NW, et al. Among authors: vokes ee. J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566. J Thorac Oncol. 2008. PMID: 18166842 Free PMC article. Clinical Trial.
568 results